Incannex Healthcare Surges to 405th in Market Rankings with 2.58 Billion in Trading Volume

On July 18, 2025, Incannex Healthcare (IXHL) saw a significant surge in trading volume, reaching 2.58 billion, a 536.97% increase from the previous day. This surge placed Incannex at the 405th position in the day's stock market rankings, with the stock price rising by 64.82%.

Incannex Healthcare Limited has announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled "Cannabinoid Compositions and Methods for Treating Pain." This patent covers the use of specific cannabinoid compositions for the treatment of pain, including chronic pain and neuropathic pain. The allowance of this patent is a significant milestone for Incannex, as it strengthens the company's intellectual property portfolio and positions it as a leader in the development of cannabinoid-based therapies for pain management.

Incannex Healthcare Limited has also announced that it has entered into a strategic partnership with a leading pharmaceutical company to co-develop and commercialize its cannabinoid-based therapies for the treatment of pain. This partnership will leverage the expertise and resources of both companies to accelerate the development and commercialization of Incannex's cannabinoid-based therapies, with the goal of bringing these innovative treatments to patients in need as quickly as possible.

Incannex Healthcare Limited has also announced that it has received approval from the Australian Therapeutic Goods Administration (TGA) for its cannabinoid-based therapy for the treatment of chronic pain. This approval is a significant milestone for Incannex, as it represents the first regulatory approval for one of its cannabinoid-based therapies. The approval of this therapy is expected to drive significant revenue growth for Incannex, as it expands its product portfolio and enters new markets.